Dublin, March 30, 2026 (GLOBE NEWSWIRE) — The “Advanced Melanoma Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The advanced melanoma market has demonstrated robust growth, expanding from $4.12 billion in 2025 to a projected $4.5 billion in 2026, registering a CAGR of 9.3%. This surge is primarily driven by a lack of treatment options in advanced stages, rising melanoma incidence, and enhanced hospital infrastructure. Increased adoption of chemotherapy and biological therapies also play crucial roles.
Looking ahead, the market is poised to reach $6.37 billion by 2030, maintaining a CAGR of 9.1%. Key factors contributing to this growth include advancements in immune checkpoint inhibitors, the proliferation of targeted therapies such as BRAF and MEK inhibitors, and personalized medicine approaches. The industry is seeing heightened investment in melanoma research, integration of digital health solutions, and an increasing focus on clinical trials and advanced melanoma research.
A notable driver of the advanced melanoma market is the rising incidence of severe sunburn, linked to UV exposure and climate change. For example, Melanoma Focus reported 201 hospital admissions in the UK in 2022-23 due to sunburn, with a significant portion affecting young children. This suggests a correlation between early-age sunburns and melanoma incidence, further fueling market growth.
Major industry players are dedicating resources to innovative solutions, like personalized vaccines, to improve treatment outcomes and overcome resistance mechanisms. Merck & Co. Inc. and Moderna Inc. have received PRIME designation for their investigational personalized mRNA cancer vaccine, mRNA-4157/V940, used with Merck’s KEYTRUDA for high-risk stage III/IV melanoma patients post-resection.
In a strategic acquisition, Pfizer Inc. acquired Seagen Inc. for $43 billion in December 2023, doubling its oncology pipeline and enhancing Seagen’s ADC technology. This aligns with a broader industry trend towards investing in cutting-edge biologics and therapeutic advancements for advanced melanoma.
The advanced melanoma market is dominated by key players such as Pfizer, F Hoffmann-La Roche, Merck, Bristol-Myers Squibb, AstraZeneca, and Novartis, among others. North America remains the largest region, while Asia-Pacific is anticipated to experience the fastest growth. Regions covered include Asia-Pacific, Western and Eastern Europe, North and South America, and Africa, with countries like Australia, Brazil, China, Germany, and the USA playing pivotal roles.
Reasons to Purchase:
- Unlock a global perspective on the advanced melanoma market spanning 16 geographies.
- Analyze the impact of macro factors, including geopolitical conflicts and evolving regulatory landscapes.
- Develop regional and country strategies based on tailored data and analysis.
- Identify and invest in growth segments.
- Gain a competitive edge using forecast data, drivers, and market trends.
- Understand consumer preferences through end-user analysis.
- Benchmark performance against key competitors focusing on market share and innovation.
- Evaluate total addressable market (TAM) and market attractiveness scoring for potential measurement.
- Support internal and external presentations with high-quality data and analysis.
- Receive the latest data updated in an Excel data sheet and a dashboard format.
Markets Covered:
- By Therapeutics: Chemotherapy; Biological Therapy; Targeted Therapy; Immune Therapy
- By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
- By End-User: Hospitals; Cancer Research Centers; Academic Institutes; Diagnostic Centers; Ambulatory Surgical Centers; Other End Users
Subsegments:
- By Chemotherapy: Alkylating Agents; Antimetabolites; Topoisomerase Inhibitors; Other Chemotherapy Drugs
- By Biological Therapy: Monoclonal Antibodies; Interferons; Interleukins
- By Targeted Therapy: BRAF Inhibitors; MEK Inhibitors; KIT Inhibitors; Other Targeted Therapies
- By Immune Therapy: Immune Checkpoint Inhibitors; Cancer Vaccines; Oncolytic Virus Therapy; Adoptive Cell Transfer
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $4.5 Billion |
| Forecasted Market Value (USD) by 2030 | $6.37 Billion |
| Compound Annual Growth Rate | 9.1% |
| Regions Covered | Global |
The companies featured in this Advanced Melanoma market report include:
- Pfizer Inc.
- F Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- Bristol-Myers Squibb
- AstraZeneca AG
- Novartis AG
- Amgen Inc.
- BioNTech SE
- Regeneron Pharmaceuticals
- Genentech Inc.
- Exelixis Inc.
- Dynavax Technologies
- Replimune Group
- Immunocore Holdings plc
- Xencor Inc.
- Agenus Inc.
- Nektar Therapeutics
- Iovance Biotherapeutics
- Adaptimmune Therapeutics
- Immutep Ltd.
- Lytix Biopharma
For more information about this report visit https://www.researchandmarkets.com/r/ic6usr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
